News & Trends - Pharmaceuticals

Sun Pharma’s novel ophthalmic treatment now TGA approved

Health Industry Hub | February 11, 2020 |
[Total: 1    Average: 4/5]

Sun Pharma gains TGA approval of novel aqueous, nanomicellar ophthalmic ciclosporin solution, for treatment of moderate-to-severe keratoconjunctivitis sicca (dry eye), where prior use of artificial tears has not been sufficient.

CEQUA’s (ciclosporin 900 microgram/mL) novel delivery system, utilising nanomicellar technology, improves the formulation’s bioavailability and allows for a more than 10-fold increase in the aqueous solubility of ciclosporin.

According to leading Ophthalmologist from Vision Eye Institute, Associate Professor Colin Chan, Sydney, the TGA approval of an additional treatment option for dry eye disease will be welcomed by clinicians and patients alike, given the prevalence of the disease.

“Dry eye affects more than seven (7.4) per cent of the Australian population. The disease represents one of the most common reasons for seeking medical eye care, with a quarter of patients who visit ophthalmic clinics reporting symptoms of dry eye.

“Furthermore, one in five patients with dry eye are dissatisfied with their overall treatment due to lack of symptom relief, the time taken to relieve symptoms, and treatment side-effects,” said A/Prof Chan.

Ciclosporin is the first agent used in the treatment of dry eye to address the pathogenesis of the disease.

“The TGA’s approval of this novel treatment with improved solubility and tissue bioavailability, helps to fulfil a clinically unmet need for dry eye therapies especially for patients who don’t respond to previous therapies,” said A/Prof Chan.

CEQUA is a S4 product and requires a prescription. Sun Pharma is seeking PBS reimbursement for this product.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

First immunotherapy PBS listed in small cell lung cancer - Pharma News

First immunotherapy treatment PBS listed in small cell lung cancer

Health Industry Hub | February 19, 2020 |

Pharma News: Effective 1 March 2020 the first immunotherapy treatment for small cell lung cancer (SCLC) will be available on […]

More


News & Trends - Medical Technology

Blood test to improve ovarian cancer diagnosis - MedTech News

Blood test to improve ovarian cancer diagnosis

Health Industry Hub | February 19, 2020 |

MedTech News: Australian researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis […]

More


Medical

The largest healthcare event in the region - Australian Healthcare Week - Medical News

Don’t miss the largest healthcare event in the region – Australian Healthcare Week

Health Industry Hub | February 19, 2020 |

Health Industry Hub is proud to partner with and support the free-to-attend 10th Annual Australian Healthcare Week Expo, held March […]

More


News & Trends - Pharmaceuticals

BMS announces new 5-year data in advanced renal cell carcinoma - Pharma News

BMS announces new 5-year data in advanced renal cell carcinoma

Health Industry Hub | February 19, 2020 |

Pharma News: Bristol-Myers Squibb announced five-year follow-up study results demonstrating that Opdivo (nivolumab) treatment delivers superior overall survival (OS) and […]

More